Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.27
DEPO's Cash-to-Debt is ranked lower than
90% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. DEPO: 0.27 )
Ranked among companies with meaningful Cash-to-Debt only.
DEPO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 11.47 Max: No Debt
Current: 0.27
Equity-to-Asset 0.20
DEPO's Equity-to-Asset is ranked lower than
93% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. DEPO: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
DEPO' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.35 Max: 0.97
Current: 0.2
-2.63
0.97
Interest Coverage 0.27
DEPO's Interest Coverage is ranked lower than
99% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. DEPO: 0.27 )
Ranked among companies with meaningful Interest Coverage only.
DEPO' s Interest Coverage Range Over the Past 10 Years
Min: 0.27  Med: 8.12 Max: No Debt
Current: 0.27
Piotroski F-Score: 6
Altman Z-Score: 0.64
Beneish M-Score: -3.27
WACC vs ROIC
9.36%
34.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 5.02
DEPO's Operating Margin % is ranked lower than
60% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. DEPO: 5.02 )
Ranked among companies with meaningful Operating Margin % only.
DEPO' s Operating Margin % Range Over the Past 10 Years
Min: -49.06  Med: 4.94 Max: 72.49
Current: 5.02
-49.06
72.49
Net Margin % -21.41
DEPO's Net Margin % is ranked lower than
81% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. DEPO: -21.41 )
Ranked among companies with meaningful Net Margin % only.
DEPO' s Net Margin % Range Over the Past 10 Years
Min: -43.92  Med: -7.32 Max: 75.05
Current: -21.41
-43.92
75.05
ROE % -34.54
DEPO's ROE % is ranked lower than
83% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. DEPO: -34.54 )
Ranked among companies with meaningful ROE % only.
DEPO' s ROE % Range Over the Past 10 Years
Min: -90.05  Med: -1.11 Max: 532.43
Current: -34.54
-90.05
532.43
ROA % -7.58
DEPO's ROA % is ranked lower than
76% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. DEPO: -7.58 )
Ranked among companies with meaningful ROA % only.
DEPO' s ROA % Range Over the Past 10 Years
Min: -23.58  Med: -1.25 Max: 73.87
Current: -7.58
-23.58
73.87
ROC (Joel Greenblatt) % 19.06
DEPO's ROC (Joel Greenblatt) % is ranked higher than
63% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. DEPO: 19.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DEPO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2282.52  Med: 65.03 Max: 8060.52
Current: 19.06
-2282.52
8060.52
3-Year Revenue Growth Rate 47.20
DEPO's 3-Year Revenue Growth Rate is ranked higher than
95% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. DEPO: 47.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DEPO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.4  Med: 39.55 Max: 517.8
Current: 47.2
-74.4
517.8
3-Year EBITDA Growth Rate 95.70
DEPO's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. DEPO: 95.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DEPO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.3  Med: 7.6 Max: 95.7
Current: 95.7
-55.3
95.7
GuruFocus has detected 4 Warning Signs with Depomed Inc $DEPO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DEPO's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DEPO Guru Trades in Q2 2016

Joel Greenblatt 47,318 sh (New)
John Hussman Sold Out
Steven Cohen Sold Out
» More
Q3 2016

DEPO Guru Trades in Q3 2016

Jeremy Grantham 102,300 sh (New)
John Hussman 100,000 sh (New)
Joel Greenblatt 77,542 sh (+63.87%)
Jeremy Grantham 500,000 sh (unchged)
» More
Q4 2016

DEPO Guru Trades in Q4 2016

Mario Gabelli 15,000 sh (New)
Jeremy Grantham 256,509 sh (+150.74%)
John Hussman 150,000 sh (+50.00%)
Jeremy Grantham 500,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q1 2017

DEPO Guru Trades in Q1 2017

Paul Tudor Jones 19,800 sh (New)
Joel Greenblatt 60,893 sh (New)
Jim Simons 218,438 sh (New)
Mario Gabelli 47,000 sh (+213.33%)
John Hussman 304,200 sh (+102.80%)
Jeremy Grantham Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:ACBFF, OTCPK:APHQF, NAS:FLXN, NAS:AMPH, NYSE:LCI, NAS:HRTX, NAS:SCMP, NAS:SCLN, NAS:KPTI, NAS:TLGT, NAS:ACET, NAS:INNL, NAS:SGYP, NAS:LBIO, NAS:AQXP, NAS:ADMS, OTCPK:TWMJF, NAS:RIGL, NAS:TOCA, NAS:TTPH » details
Traded in other countries:DPO.Germany,
Headquarter Location:USA
Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed is a specialty and generic drug manufacturer. The company is focused on pain and central nervous system conditions. Depomed operates solely in the United States. It also has recognized license and royalty revenue from license agreements in the territories of the U.S., Canada, and Korea. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Depomed Inc

Depomed to Present at the UBS Global Healthcare Conference
Depomed to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration
Depomed Announces Prepayment of $100 Million of Secured Debt Facility
Depomed Announces Cooperation Agreement with Starboard Value LP Including CEO and Board Changes

-Pharmaceutical Veteran Arthur J. Higgins Joins as President, CEO and Director-
-Three New Directors Named to Board- -James Fogarty Named New Chairman of the Board- -Q1 2017 Net Sales Estimated to be $95-$100 Million- NEWARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that Arthur J. Higgins has joined the Company as President and Chief Executive Officer and member of the Board of Directors, following the resignation of James Schoeneck as President and Chief Executive Officer and member of the Board of Directors.  Mr. Higgins is a highly respected executive with over 35 years’ experience in the pharmaceutical and healthcare industry.  Serving as CEO of Bayer Healthcare, he helped transform the company into a leader in global pharmaceutical and consumer healthcare.  He previously served as Chairman and CEO of Enzon, Inc., and President of Abbott Laboratories Pharmaceuticals Division, and more recently has served as Senior Advisor to The Blackstone Group.   “I am honored to be able to work with the management and the Board of Depomed.  We have an opportunity to accelerate Depomed’s journey as a leader in pain management and neurology as we maximize value for all shareholders,” said Mr. Higgins.  Composition of the Board Depomed also announced that Mr. Higgins, William McKee, former Chief Financial Officer of Barr Pharmaceuticals, LLC, and Gavin Molinelli, a partner at Starboard Value LP have joined the Board of Directors, and that Samuel Saks, M.D. and David Zenoff, D.B.A. have resigned from the Board.  Karen Dawes, James Fogarty, Louis Lavigne, Jr., Robert Savage, Peter Staple and James Tyree will continue as members of the Board.  James Fogarty will serve as the new Chairman of the Board. Peter Staple said, "On behalf of the Board, I want to thank Sam Saks and David Zenoff for their contributions as directors. They have each played an important role in the Company's growth and have provided the rest of the Board and the management team with valuable insights and leadership over many years." “We are pleased to have reached an agreement to work with Depomed.  We believe that Arthur Higgins is an excellent choice to lead Depomed. We are excited to have found such a qualified leader for the Company.  Furthermore, we believe the addition of William McKee as a member of the Board of Directors will add valuable industry experience to the boardroom.  I look forward to working with my fellow board members to maximize value for all shareholders,” said Gavin Molinelli, Partner of Starboard Value LP. William McKee is a pharmaceutical industry consultant and board member of Cerulean Pharma, Inc. and Agile Therapeutics.  Formerly, Mr. McKee served as COO and CFO at EKR Therapeutics, Inc., a private specialty pharmaceutical company, until EKR was sold to Cornerstone Therapeutics Inc.  Prior to that, Mr. McKee served as the Executive Vice President and Chief Financial Officer of Barr Pharmaceuticals Inc., a public specialty pharmaceutical company, which was acquired by Teva Pharmaceutical Industries Ltd. Gavin Molinelli is a Partner of Starboard Value LP.  Prior to joining Starboard and its related funds in 2006, Mr. Molinelli was a member of the Technology Investment Banking group at Banc of America Securities LLC.  Mr. Molinelli was formerly on the Board of Directors of Wausau Paper Corp. and Actel Corporation. First Quarter Results Depomed also announced that it estimates net sales for the quarter ending March 31, 2017 will be approximately $95 to $100 million.  First quarter results reflect the impact of the previously announced realignment of the Company’s sales force effective February 1, 2017 and the fact that the Company had a significant number of openings in its field sales force in the first quarter, as well as wholesalers’ reductions of inventory of our products in the first quarter and continued weakness in the long-acting and short-acting opioid markets.
  The Company will revise its financial guidance for the year at its earnings call for the first quarter which is expected to take place in the week of May 8, 2017.    About Depomed Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com. About Starboard Value LP Starboard Value LP is a New York-based investment adviser with a focused and fundamental approach to investing in publicly traded U.S. companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to risks detailed in the Company’s Securities and Exchange Commission filings, including the Company’s most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the Company’s plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
INVESTOR AND MEDIA CONTACT:

Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]

Read more...
Depomed to Present at Healthcare Conferences in March

NEWARK, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that senior management will present at the following healthcare conferences during the month of March.
29th Annual ROTH Conference Date: Monday, March 13, 2017
Time: 3:00 p.m. PDT
Location: Dana Point, California Oppenheimer 27th Annual Healthcare Conference Date: Tuesday, March 21, 2017
Time: 8:30 a.m. EDT
Location: New York, New York These presentations will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of these events will be archived for 30 days on the company's website. About Depomed Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact:

Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]

Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 14.43
DEPO's Forward PE Ratio is ranked higher than
79% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. DEPO: 14.43 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 11.16
DEPO's Price-to-Owner-Earnings is ranked lower than
54% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. DEPO: 11.16 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DEPO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.68  Med: 7.64 Max: 212
Current: 11.16
2.68
212
PB Ratio 2.88
DEPO's PB Ratio is ranked lower than
51% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. DEPO: 2.88 )
Ranked among companies with meaningful PB Ratio only.
DEPO' s PB Ratio Range Over the Past 10 Years
Min: 2  Med: 4.24 Max: 22.64
Current: 2.88
2
22.64
PS Ratio 1.51
DEPO's PS Ratio is ranked higher than
71% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DEPO: 1.51 )
Ranked among companies with meaningful PS Ratio only.
DEPO' s PS Ratio Range Over the Past 10 Years
Min: 1.38  Med: 3.24 Max: 33.61
Current: 1.51
1.38
33.61
Price-to-Free-Cash-Flow 6.94
DEPO's Price-to-Free-Cash-Flow is ranked higher than
77% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. DEPO: 6.94 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DEPO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.37  Med: 10.74 Max: 291.05
Current: 6.94
2.37
291.05
Price-to-Operating-Cash-Flow 6.70
DEPO's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. DEPO: 6.70 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DEPO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.35  Med: 10.48 Max: 271.08
Current: 6.7
2.35
271.08
EV-to-EBIT 70.15
DEPO's EV-to-EBIT is ranked lower than
94% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. DEPO: 70.15 )
Ranked among companies with meaningful EV-to-EBIT only.
DEPO' s EV-to-EBIT Range Over the Past 10 Years
Min: -302.2  Med: -2.5 Max: 117.3
Current: 70.15
-302.2
117.3
EV-to-EBITDA 9.54
DEPO's EV-to-EBITDA is ranked higher than
59% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. DEPO: 9.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: 2.3 Max: 124.5
Current: 9.54
-582.9
124.5
Shiller PE Ratio 87.61
DEPO's Shiller PE Ratio is ranked lower than
76% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. DEPO: 87.61 )
Ranked among companies with meaningful Shiller PE Ratio only.
DEPO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 75.75  Med: 117.73 Max: 387.25
Current: 87.61
75.75
387.25
Current Ratio 0.95
DEPO's Current Ratio is ranked lower than
79% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. DEPO: 0.95 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.87 Max: 56
Current: 0.95
0.57
56
Quick Ratio 0.91
DEPO's Quick Ratio is ranked lower than
67% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. DEPO: 0.91 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.72 Max: 56
Current: 0.91
0.57
56
Days Inventory 51.45
DEPO's Days Inventory is ranked higher than
87% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. DEPO: 51.45 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 49.12  Med: 208.69 Max: 544.34
Current: 51.45
49.12
544.34
Days Sales Outstanding 55.81
DEPO's Days Sales Outstanding is ranked lower than
55% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. DEPO: 55.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 81.71
Current: 55.81
12.13
81.71
Days Payable 32.08
DEPO's Days Payable is ranked lower than
56% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. DEPO: 32.08 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 91.87 Max: 159.38
Current: 32.08
30.8
159.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.60
DEPO's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. DEPO: -2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DEPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.9  Med: -7.55 Max: -2.2
Current: -2.6
-58.9
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.44
DEPO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. DEPO: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DEPO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.18  Med: 2.45 Max: 335
Current: 1.44
1.18
335
Price-to-Median-PS-Value 0.46
DEPO's Price-to-Median-PS-Value is ranked higher than
91% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. DEPO: 0.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DEPO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 3.22 Max: 394
Current: 0.46
0.43
394
Earnings Yield (Greenblatt) % 1.40
DEPO's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. DEPO: 1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DEPO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.9  Med: 15.3 Max: 266.4
Current: 1.4
0.9
266.4

More Statistics

Revenue (TTM) (Mil) $441.6
EPS (TTM) $ -1.53
Beta1.45
Short Percentage of Float22.58%
52-Week Range $9.50 - 27.02
Shares Outstanding (Mil)62.34

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 444 502 553
EPS ($) 0.82 1.11 1.13
EPS without NRI ($) 0.82 1.11 1.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
25.00%
Dividends per Share ($)
» More Articles for NAS:DEPO

Headlines

Articles On GuruFocus.com
Depomed to Present at the UBS Global Healthcare Conference May 16 2017 
Depomed to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 May 02 2017 
Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Adm Apr 25 2017 
Depomed Announces Prepayment of $100 Million of Secured Debt Facility Apr 04 2017 
Depomed Announces Cooperation Agreement with Starboard Value LP Including CEO and Board Changes Mar 28 2017 
Depomed to Present at Healthcare Conferences in March Mar 06 2017 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 

More From Other Websites
Depomed Announces Corporate Governance Updates May 22 2017
Depomed to Present at the UBS Global Healthcare Conference May 16 2017
Today's Research Reports on Stocks to Watch: Rexahn Pharmaceuticals and Depomed May 12 2017
Edited Transcript of DEPO earnings conference call or presentation 9-May-17 8:30pm GMT May 10 2017
Depomed Focuses on Flagship Drug Rather Than M&A: CEO May 10 2017
Biotech Movers: Depomed Shares Tank After Losses Get Even Worse May 10 2017
Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More May 10 2017
Depomed reports 1Q loss May 09 2017
Depomed shares down 13% after earnings miss May 09 2017
Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving... May 09 2017
Investor Network: Depomed, Inc. to Host Earnings Call May 09 2017
One Year Later: A Look At The 2016 Ira Sohn Conference Picks May 08 2017
Depomed to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 May 02 2017
Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and... Apr 25 2017
Which Drugmakers Will Rock The Sector In Q1? Apr 13 2017
STRATA Skin Sciences and Depomed Recover from Wednesday's FDA Opioid Shockwave Apr 10 2017
DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control Apr 05 2017
Depomed Announces Prepayment of $100 Million of Secured Debt Facility Apr 04 2017
Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest Mar 31 2017
How Much Pain Will Congress Inflict on These Opioid Drugmakers' Stocks? Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}